IE 11 is not supported. For an optimal experience visit our site on another browser.

Video Interview: Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc. (AVNR)

NEW YORK, Feb. 4, 2011 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc. to discuss the company's industry, strategy, financials and positioning.
/ Source: GlobeNewswire

NEW YORK, Feb. 4, 2011 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc. to discuss the company's industry, strategy, financials and positioning.

Click here to view video:

Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc.

Mr. Katkin joined AVANIR in July 2005 as Senior Vice President of Sales and Marketing. In March 2007, Mr. Katkin was appointed President and Chief Executive Officer and was elected as a member of the Board of Directors. Prior to joining AVANIR, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, playing a key role in the management of the company and its sale to Johnson and Johnson. Additionally, Mr. Katkin's employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories.

Mr. Katkin received a Bachelor of Science degree in Business and Accounting from Indiana University and an MBA degree in Finance from the Anderson School of Management at UCLA, graduating with honors. Mr. Katkin became a licensed Certified Public Accountant in 1995.

About AVANIR Pharmaceuticals, Inc. (AVNR):

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. The Company recently received approval from the U.S. Food and Drug Administration (FDA) for NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate), the first and only FDA-approved treatment for pseudobulbar affect (PBA), a neurologic condition causing involuntary, sudden and frequent episodes of laughing and crying. For the full Prescribing Information and Important Safety Information, please visit , and for more information about AVANIR, please visit .

For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839